Our results indicate that this new model allows convenient and sensitive real-time monitoring of cellular approaches for immunotherapy of multiple myeloma-like tumors with different immunogenicities. This model, therefore, allows comprehensive preclinical evaluation of novel combination therapies for multiple myeloma.
No takes yet. Share an insight, caveat, or question.
Rozemuller et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: